PE PREMIER CHINA CLINICAL TRIAL

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

Also called NCT02230254

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 101 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02230254
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02230254. Allocation not applicable; no masking; primary purpose treatment. Start 2014-04-09 (actual); primary completion 2014-06-22 (actual). Results posted on 2022-05-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PE PREMIER CHINA CLINICAL TRIAL
Condition
Atherosclerosis
Intervention (Device)
Percutaneous coronary intervention PROMUS PREMIER
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct02230254
Content hash
cd98c5bfcd96e19811fe3d0be131b876f622776cedb603f13fa32457656c405e